Specific active immunotherapy does not prolong survival in surgically treated patients with stage IIB malignant melanoma and may promote early recurrence.

A prospective trial with concurrent controls was designed to assess the effects of specific active immunotherapy in patients receiving intermittent cytotoxic chemotherapy (DTIC + Vincristine) as an adjuvant to surgery in Stage IIB malignant melanoma. The treated group received monthly irradiated all...

Descripción completa

Detalles Bibliográficos
Autores principales: Hedley, D. W., McElwain, T. J., Currie, G. A.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1978
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2009555/
https://www.ncbi.nlm.nih.gov/pubmed/646922

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2009555/
https://www.ncbi.nlm.nih.gov/pubmed/646922

Ejemplares similares